XLRN - Acceleron Pharma Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Acceleron Pharma Inc.

128 Sidney Street
Cambridge, MA 02139
United States

Full Time Employees173

Key Executives

NameTitlePayExercisedYear Born
Mr. Habib J. DableCEO, Pres & Director974.38kN/A1969
Dr. Thomas P. ManiatisCo-Founder, Member of Scientific Advisory Board & Director Emeritus45kN/A1943
Mr. Kevin F. McLaughlinSr. VP, CFO & Treasurer591.17k1.42M1956
Dr. John D. QuiselExec. VP & Chief Bus. Officer632.39kN/A1971
Mr. Sujay R. KangoSr. VP & Chief Commercial Officer921.92kN/A1964
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Acceleron Pharma Inc.’s ISS Governance QualityScore as of July 29, 2019 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 6; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.